Merck is urged by patient groups to ensure widespread access to an HIV prevention pill being tested A late-stage study is not expected to be over until next year, but advocates want a commitment now

https://www.statnews.com/pharmalot/2026/02/11/merck-aids-hiv-access-gilead-pricing/ By Ed SilvermanFeb. 11, 2026 Pharmalot Columnist, Senior Writer